Tenosynovitis
Methodology & AI Transparency ⓘ
Tenosynovitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry M65.90: Tenosynovitis is managed within Arthritis & Joints.
- 3 Typical cash cost range: Workup highlights for Tenosynovitis (M65.90): urate-lowering titration [Tenosynovitis M65.90].
- 4 Top reported side effects / signs: Objective lab/clinical target for Tenosynovitis: Serum Uric Acid in Tenosynovitis (M65.90: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M65.90)) and hs-CRP & Erythrocyte in Tenosynovitis (M65.90: Sedimentation Rate).
Ask our AI Specialists anything about Tenosynovitis
What Is Tenosynovitis?
Recognized across U.S. clinical coding as M65.90 (Arthritis & Joints), Tenosynovitis is evaluated via urate-lowering titration [Tenosynovitis M65.90] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Tenosynovitis (M65.90) involves monosodium urate or in Tenosynovitis (M65.90: calcium pyrophosphate crystal). progression correlates with shifts in Serum Uric Acid in Tenosynovitis (M65.90: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M65.90)).
Common Symptoms & Clinical Signs
- • Presentation of Tenosynovitis (M65.90): brief morning joint in Tenosynovitis (M65.90: stiffness)
- • Secondary Tenosynovitis clinical sign: sudden, intensely painful, in Tenosynovitis (M65.90: red swollen big-toe)
- • Symptom flares in Tenosynovitis correlating with Serum Uric Acid in Tenosynovitis (M65.90: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M65.90)
- • Functional arthritis & joints impact requiring urate-lowering titration [Tenosynovitis M65.90] evaluation (M65.90)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Tenosynovitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M65.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Tenosynovitis (M65.90: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M65.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Tenosynovitis (M65.90: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M65.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Tenosynovitis M65.90] | Preserved joint-space width (M65.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Tenosynovitis
Treatment selection for Tenosynovitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tenosynovitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on A population how the body absorbs the medicine model using allometric scaling for The PK modeling suggested the optimal dosing regimen based on weight for children patients as: 2-mg QD for patients 10 to <30 kg and 4-mg QD for patients ≥30 kg. CPT: pharmacometrics & systems pharmacology • 2024-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38532270 ↗ |
| Can This Approach Help? Inside the Latest Research on Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA. The Journal of rheumatology • 2022-07-15 • Phase III Randomized Trial | N = 126 | 88/100 | PMID 35428720 ↗ |
| New Insights on Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis:: What a 851-Participant Study Found Improved outcomes were observed more in. The Journal of rheumatology • 2022-08-15 • Phase III Randomized Trial | N = 851 | 87/100 | PMID 35428718 ↗ |
Tenosynovitis Patient Community & “People Like Me” Threads
Filter Tenosynovitis community threads and patient logs by age, biological sex, dosage, and treatment duration.